Truist Financial maintained a Buy rating on AdaptHealth, noting that the company could benefit from Trump-era tariffs.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Truist Financial maintained a Buy rating on AdaptHealth, noting that the company could benefit from Trump-era tariffs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AdaptHealth
health care services
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
Related events
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- Donald Trump announced tariffs and the elimination of tax credits.
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Trump's tariffs spooked markets, specifically impacting MSCI.
Coverage
Newest first; wire copies grouped- Insider MonkeyTruist Financial Remains Bullish on AdaptHealth (AHCO) AdaptHealth Corp. (NASDAQ:AHCO) is one of the best undervalued medical device stocks to buy now. In a report released on July 1, David S Macdona